Evidence map›Paper›PMID 39984744›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study.

Solène Malmon, Olivier Casasnovas, Marguerite Fournier, Guillaume Cartron, Salim Kanoun, Anne Ségolène Cottereau, Charles Herbaux, Yassine Al Tabaa

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Solène MalmonPixilib SAS, Toulouse, France.
Olivier CasasnovasDepartment of Hematology, Dijon Bourgogne University Hospital and INSERM UMR 1231, Dijon, France.
Marguerite FournierDepartment of Biostatistics, LYSARC, Lyon-Sud Hospital, Pierre-Bénite, France.
Guillaume CartronDepartment of Clinical Hematology, CHU Montpellier, Montpellier, France.
Salim KanounCancer Research Center of Toulouse, Team 9, INSERM Unité Mixte de Recherche 1037, Toulouse, France.
Anne Ségolène CottereauDepartment of Nuclear Medicine, Cochin Hospital, AP-HP, University of Paris Cité, Paris, France.
Charles HerbauxDepartment of Clinical Hematology, CHU Montpellier, Montpellier, France.
Yassine Al TabaaScintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier, France. yassine.altabaa@scintidoc.fr.ORCID 0000-0001-8104-9874

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTotal metabolic tumor volume (TMTV) at baseline becomes a key biomarker in several lymphoma subtypes. Variability in segmentation methods such as 41%SUVmax and SUVmax > 4 has limited its clinical application. Additionally, immune-checkpoint-inhibitors introduced challenges in response assessment due to pseudoprogression, complicating the use of traditional metrics. This study investigates the prognostic impact of baseline- and residual-TMTV and introduces a novel personalized-liver-based-threshold (pTMTV

methodsWe analyzed 91 patients with relapsed/refractory diffuse-large-B-cell lymphoma and follicular lymphoma from the GATA trial, comparing patient's outcome according to three segmentation methods: TMTV

resultsBaseline-TMTV significantly influenced prognosis with higher TMTV correlating with shorter PFS and OS (p < 0.0001 for all methods). Residual-TMTV, particularly with pTMTV

conclusionBaseline- and residual-TMTV strongly influence prognosis and response in lymphoma patients. The novel personalized pTMTV

Indexed as

Lymphoma, FollicularLymphoma, Large B-Cell, DiffusePrecision MedicineTumor BurdenAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyPrognosisRecurrenceTreatment OutcomeBaseline TMTVLymphomaPatient based segmentation methodPatient outcomes stratificationPET/CTResidual TMTV

Identifiers

PMID39984744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.